148 related articles for article (PubMed ID: 18977148)
1. Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.
Clement JA; Kitagaki J; Yang Y; Saucedo CJ; O'Keefe BR; Weissman AM; McKee TC; McMahon JB
Bioorg Med Chem; 2008 Dec; 16(23):10022-8. PubMed ID: 18977148
[TBL] [Abstract][Full Text] [Related]
2. Additional cytotoxic pyridoacridine alkaloids from the ascidian Cystodytes violatinctus and biogenetic considerations.
Bontemps N; Gattacceca F; Long C; Thomas OP; Banaigs B
J Nat Prod; 2013 Sep; 76(9):1801-5. PubMed ID: 23961991
[TBL] [Abstract][Full Text] [Related]
3. Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.
Kitagaki J; Agama KK; Pommier Y; Yang Y; Weissman AM
Mol Cancer Ther; 2008 Aug; 7(8):2445-54. PubMed ID: 18723490
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting Hdm2 and ubiquitin-activating enzyme: targeting the ubiquitin conjugating system in cancer.
Weissman AM; Yang Y; Kitagaki J; Sasiela CA; Beutler JA; O'Keefe BR
Ernst Schering Found Symp Proc; 2008; (1):171-90. PubMed ID: 19202599
[TBL] [Abstract][Full Text] [Related]
5. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells.
Yang Y; Ludwig RL; Jensen JP; Pierre SA; Medaglia MV; Davydov IV; Safiran YJ; Oberoi P; Kenten JH; Phillips AC; Weissman AM; Vousden KH
Cancer Cell; 2005 Jun; 7(6):547-59. PubMed ID: 15950904
[TBL] [Abstract][Full Text] [Related]
6. Sebastianines A and B, novel biologically active pyridoacridine alkaloids from the Brazilian ascidian Cystodytes dellechiajei.
Torres YR; Bugni TS; Berlinck RG; Ireland CM; Magalhães A; Ferreira AG; Moreira Da Rocha R
J Org Chem; 2002 Jul; 67(15):5429-32. PubMed ID: 12126446
[TBL] [Abstract][Full Text] [Related]
7. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors.
Lai Z; Yang T; Kim YB; Sielecki TM; Diamond MA; Strack P; Rolfe M; Caligiuri M; Benfield PA; Auger KR; Copeland RA
Proc Natl Acad Sci U S A; 2002 Nov; 99(23):14734-9. PubMed ID: 12407176
[TBL] [Abstract][Full Text] [Related]
8. p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction.
Medina-Medina I; Martínez-Sánchez M; Hernández-Monge J; Fahraeus R; Muller P; Olivares-Illana V
Protein Sci; 2018 May; 27(5):976-986. PubMed ID: 29524278
[TBL] [Abstract][Full Text] [Related]
9. Structures and antimicrobial activities of pyridoacridine alkaloids isolated from different chromotypes of the ascidian Cystodytes dellechiajei.
Bontemps N; Bry D; López-Legentil S; Simon-Levert A; Long C; Banaigs B
J Nat Prod; 2010 Jun; 73(6):1044-8. PubMed ID: 20491501
[TBL] [Abstract][Full Text] [Related]
10. Siladenoserinols A-L: new sulfonated serinol derivatives from a tunicate as inhibitors of p53-Hdm2 interaction.
Nakamura Y; Kato H; Nishikawa T; Iwasaki N; Suwa Y; Rotinsulu H; Losung F; Maarisit W; Mangindaan RE; Morioka H; Yokosawa H; Tsukamoto S
Org Lett; 2013 Jan; 15(2):322-5. PubMed ID: 23268733
[TBL] [Abstract][Full Text] [Related]
11. 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.
Dickens MP; Roxburgh P; Hock A; Mezna M; Kellam B; Vousden KH; Fischer PM
Bioorg Med Chem; 2013 Nov; 21(22):6868-77. PubMed ID: 24113239
[TBL] [Abstract][Full Text] [Related]
12. Quantitative assays of Mdm2 ubiquitin ligase activity and other ubiquitin-utilizing enzymes for inhibitor discovery.
Auger KR; Copeland RA; Lai Z
Methods Enzymol; 2005; 399():701-17. PubMed ID: 16338390
[TBL] [Abstract][Full Text] [Related]
13. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26.
Zhang Y; Wang J; Yuan Y; Zhang W; Guan W; Wu Z; Jin C; Chen H; Zhang L; Yang X; He F
Nucleic Acids Res; 2010 Oct; 38(19):6544-54. PubMed ID: 20542919
[TBL] [Abstract][Full Text] [Related]
14. Diphenylpyrroles: Novel p53 activators.
Gomha SM; Eldebss TM; Abdulla MM; Mayhoub AS
Eur J Med Chem; 2014 Jul; 82():472-9. PubMed ID: 24934571
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
16. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
17. [Abnormal p53-HDM2 interaction in hematological malignancy].
Tabe Y; Kojima K
Nihon Rinsho; 2014 Jun; 72(6):1042-6. PubMed ID: 25016801
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitors suppress the protein expression of mutant p53.
Halasi M; Pandit B; Gartel AL
Cell Cycle; 2014; 13(20):3202-6. PubMed ID: 25485499
[TBL] [Abstract][Full Text] [Related]
19. Pyridoacridine alkaloids inducing neuronal differentiation in a neuroblastoma cell line, from marine sponge Biemna fortis.
Aoki S; Wei H; Matsui K; Rachmat R; Kobayashi M
Bioorg Med Chem; 2003 May; 11(9):1969-73. PubMed ID: 12670647
[TBL] [Abstract][Full Text] [Related]
20. Lissoclibadins 4-7, polysulfur aromatic alkaloids from the Indonesian ascidian Lissoclinum cf. badium.
Nakazawa T; Xu J; Nishikawa T; Oda T; Fujita A; Ukai K; Mangindaan RE; Rotinsulu H; Kobayashi H; Namikoshi M
J Nat Prod; 2007 Mar; 70(3):439-42. PubMed ID: 17269824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
